UCB SA (OTCMKTS:UCBJF – Get Free Report)’s share price passed above its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $192.24 and traded as high as $194.91. UCB shares last traded at $194.90, with a volume of 1,000 shares changing hands.
UCB Trading Up 1.6 %
The firm has a fifty day moving average of $192.24 and a 200-day moving average of $185.83. The company has a quick ratio of 0.78, a current ratio of 1.19 and a debt-to-equity ratio of 0.33.
About UCB
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.
See Also
- Five stocks we like better than UCB
- How to Invest in Small Cap Stocks
- Arqit Stock Soars as NVIDIA’s GTC Fuels Quantum Excitement
- How to buy stock: A step-by-step guide for beginners
- 3 Must-Own Stocks to Build Wealth This Decade
- What Do S&P 500 Stocks Tell Investors About the Market?
- Advanced Micro Devices Eyes AI Market Growth—Is AMD a Buy?
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.
